Gene Therapy a New Milestone in Immunotherapy
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer.
CancerCare® Expands Financial Assistance for Cancer Patients Affected by Hurricanes
As part of its mission to provide help and hope to anyone affected by a cancer diagnosis, CancerCare® is offering direct financial assistance to cancer patients residing in the United States, including Puerto Rico and the U.S. Virgin Islands, who have been impacted by Hurricanes Harvey, Irma, Jose or Maria.
Tecentriq Now Approved as First Treatment for Advanced Bladder Cancer in Some Patients
FDA Approvals, News & UpdatesNewsworthy
On April 17, 2017, the FDA approved the PD-L1 inhibitor Tecentriq (atezolizumab; from Genentech) for use as first-line treatment for patients with locally advanced or metastatic urothelial carcinoma who cannot use cisplatin chemotherapy.
Kisqali a New First-Line Treatment for Patients with Advanced Breast Cancer
FDA Approvals, News & UpdatesNewsworthy
In March 2017, the FDA approved Kisqali (ribociclib), in combination with an aromatase inhibitor, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Page 5 of 6
Results 41 - 50 of 60

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.